16th May 2017 BSBMT Scientific Day

Presentations with permissions now available to view/download

Session 1: Targeted Conditioning for Stem Cell Transplant
- Development of antibody based conditioning agents for transplant: towards more targeted therapy? - Dr Agnieszka Czechowicz, Stanford University, USA
- Clinical application of radiolabelled antibodies as conditioning agents - Dr Kim Orchard, University Hospital Southampton

Session 2: The John Goldman Abstract Prize Competition
- Redirection of therapeutic T cells to a bone marrow memory niche improves their persistence and function - Dr Anjum Khan, UCL Cancer Institute
- Mixed chimerism following haemopoietic stem cell transplantation is maintained by peripheral tolerance mediated by host and donor regulatory T cells - Dr Francesca Kinsella, University of Birmingham
- Number of CD56dim NK cells in the graft has a major impact on risk of disease relapse following allo-HSCT - Dr Luke Maggs, University of Birmingham
- Successful outcome following allogeneic hematopoietic stem cell transplantation in adult patients with inherited primary immunodeficiency - Professor Emma Morris, University College London
- Prolonged persistence of therapeutic T cells after therapy with a novel CD19CAR in paediatric ALL patients: preliminary results from the CARPALL study (NCT02443831) - Dr Sara Ghorashian, University College London
- Donor Lymphocyte infusion after T-cell depleted reduced intensity conditioning haematopoietic stem cell transplant is safe and has significant clinical activity - Dr Sandeep Nagra, University Hospitals Birmingham

Congratulations to Dr Francesca Kinsella and Sara Ghorashian for winning the Abstract Prizes.

Session 3 - BSBMT Open Meeting

Session 4 - BSBMT-CTC IMPACT: Prospective UK BMT Trials
- BSBMT CTC prospective studies - Dr Andy Peniket, Oxford University Hospitals
- A Phase I study of BK-virus-specific T-cells in treatment of haemorrhagic cystitis after haematopoietic cell transplantation - Dr Eduardo Olavarria, Imperial College Healthcare
- IMPACT - Professor David Marks, University Hospitals Bristol
- Multi-centre randomized controlled study comparing fludarabine, melphalan and campath vs cyclosphosphamide (120mg/kg) plus 8 Gy of TBI as conditioning for reduced intensity allografts for patients >40 years with ALL in CR1- Professor David Marks, University Hospitals Bristol
- FIGARO2 - Professor Charles Craddock, University Hospitals Birmingham
- A phase II prospective trial of prophylactic donor lymphocyte infusions for the prevention of relapse post HSCT in patients with high risk myeloid malignancy - Dr Victoria Potter, King’s College Hospital
- Developing future lymphoma transplant studies - Dr Ram Malladi, University Hospitals Birmingham